

Patient Associations Disclosure 2022

Novo Nordisk is committed to providing ongoing support for patient associations in therapeutic areas where we feel we can make a difference. This includes financial and non-financial support in the form of sponsorship of educational meetings, activities and charitable donations.

In 2022, Novo Nordisk supported Diabetes Ireland, European Coalition For People Living with Obesity, Irish Coalition of People Living with Obesity & Irish Haemophilia Society.

In total, the financial value of this support was €165,798 and is detailed as follows:

- Corporate sponsorship with Diabetes Ireland in the form of a gold card membership (€20,000), a grant for an awareness video (€11,838), a grant for the formation of a working group (€13,320), a grant for the launch of the SMART programme (€8,558) and honoraria donations (€898)
- Support to the European Coalition For People Living with Obesity in the form of a grant for the 'Voice of Youth' Campaign (€76,000) and a project (€15,700)
- Grant to the Irish Coalition of People Living with Obesity to support their education and awareness building (€10,140) and attendance at EOPAS congress (€1844)
- Corporate sponsorship with Irish Haemophilia Society in the form of a gold sponsorship (€7,500),

This disclosure is made in compliance with Irish Pharmaceutical Healthcare Association Code of Practice for the Pharmaceutical Industry, Annex III: Guideline for Companies on Working with Patient Associations

The Apis bull logo is a registered trademark owned by Novo Nordisk A/S

IE23NNG00032, June 2023

